WST
$239.42
West Pharmaceutical Services, Inc.
Intraday
Recent News
The Zacks Analyst Blog Highlights Atmos Energy, Colgate-Palmolive and West Pharmaceutical Services
Dividend Aristocrats like Atmos Energy, Colgate-Palmolive and West Pharmaceutical Services offer steady income as geopolitical tensions and oil price spikes rattle markets.
Will CEO Succession and Chair Role Debate Reshape West Pharmaceutical’s Governance Story (WST)?
In early March 2026, West Pharmaceutical Services announced that long-time President, CEO and Board Chair Eric M. Green plans to retire in the second half of 2026, reaffirmed its February 12, 2026 guidance, and later received a shareholder proposal seeking to permanently separate the CEO and Chair roles, which the company urged investors to vote against at its May 4, 2026 annual meeting. This combination of a planned leadership transition, strong Q4 2025 results with reaffirmed guidance, and...
3 Dividend Aristocrats to Buy Now Amid the Middle East Crisis
Middle East tensions rattle markets as oil tops $100. Atmos Energy, Colgate-Palmolive and West Pharmaceutical Services stand out as dividend aristocrats for stability.
How Is West Pharmaceutical's Stock Performance Compared to Other Healthcare Stocks?
Despite West Pharmaceutical's underperformance relative to its peers on a YTD basis, Wall Street analysts remain strongly optimistic about the stock’s prospects.
Reasons to Add West Pharmaceutical Stock to Your Portfolio Right Now
WST eyes growth from high-value components, GLP-1 drug demand and Annex 1 conversions, but generics destocking and European capacity constraints pose risks.